New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
05:44 EDTAKERAkers Biosciences starts clinical trials for PIFA PLUSS Chlamydia assay
Akers Biosciences has commenced clinical trials in the USA for its PIFA PLUSS Chlamydia Assay, the world's first rapid test for Chlamydia diagnosis using a finger stick blood sample. The study will consist of three populations of patients totaling 200-250 subjects; the population groups will contain normal, newly infected and actively infected subjects, as well as previously infected and treated subjects. It is estimated that the study will last approximately three months, but that time could be extended based on the prevalence of Chlamydia-positive subjects. Regulatory documentation will be submitted in both the U.S. and EU shortly after conclusion of the studies with a view towards seeking regulatory approval to sell the tests. ABI's PIFA PLUSS Chlamydia Assay, based on the company's proprietary particle immunofiltration assay technology, provides results in approximately five minutes. ABI's assay was designed to make screening widely available and easy and, unlike current testing procedures, the Company's assay can be run in a wide range of settings including doctors' offices, clinics and school or university health centers. The company believes that the test, once approved in the U.S., will be eligible for insurance reimbursement.
News For AKER From The Last 14 Days
Check below for free stories on AKER the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
05:47 EDTAKERAkers announces U.S. patent granted for Breath Ketone detection device
Subscribe for More Information
July 16, 2014
07:23 EDTAKERRedChip Companies to hold a virtual conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use